Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilitie...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ning, Yan, Limei, Shan, Fengping, Wang, Xiaonai, Qu, Na, Handley, Mike K, Ma, Mingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859308/
https://www.ncbi.nlm.nih.gov/pubmed/33540155
http://dx.doi.org/10.1016/j.tranon.2021.101028
_version_ 1783646702612250624
author Liu, Ning
Yan, Limei
Shan, Fengping
Wang, Xiaonai
Qu, Na
Handley, Mike K
Ma, Mingxing
author_facet Liu, Ning
Yan, Limei
Shan, Fengping
Wang, Xiaonai
Qu, Na
Handley, Mike K
Ma, Mingxing
author_sort Liu, Ning
collection PubMed
description The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer.
format Online
Article
Text
id pubmed-7859308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-78593082021-02-09 Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway Liu, Ning Yan, Limei Shan, Fengping Wang, Xiaonai Qu, Na Handley, Mike K Ma, Mingxing Transl Oncol Original Research The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer. Neoplasia Press 2021-02-01 /pmc/articles/PMC7859308/ /pubmed/33540155 http://dx.doi.org/10.1016/j.tranon.2021.101028 Text en © 2021 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Research
Liu, Ning
Yan, Limei
Shan, Fengping
Wang, Xiaonai
Qu, Na
Handley, Mike K
Ma, Mingxing
Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway
title Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway
title_full Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway
title_fullStr Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway
title_full_unstemmed Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway
title_short Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway
title_sort low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing pi3k/akt/mtor pathway
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859308/
https://www.ncbi.nlm.nih.gov/pubmed/33540155
http://dx.doi.org/10.1016/j.tranon.2021.101028
work_keys_str_mv AT liuning lowdosenaltrexoneplaysantineoplasticroleincervicalcancerprogressionthroughsuppressingpi3kaktmtorpathway
AT yanlimei lowdosenaltrexoneplaysantineoplasticroleincervicalcancerprogressionthroughsuppressingpi3kaktmtorpathway
AT shanfengping lowdosenaltrexoneplaysantineoplasticroleincervicalcancerprogressionthroughsuppressingpi3kaktmtorpathway
AT wangxiaonai lowdosenaltrexoneplaysantineoplasticroleincervicalcancerprogressionthroughsuppressingpi3kaktmtorpathway
AT quna lowdosenaltrexoneplaysantineoplasticroleincervicalcancerprogressionthroughsuppressingpi3kaktmtorpathway
AT handleymikek lowdosenaltrexoneplaysantineoplasticroleincervicalcancerprogressionthroughsuppressingpi3kaktmtorpathway
AT mamingxing lowdosenaltrexoneplaysantineoplasticroleincervicalcancerprogressionthroughsuppressingpi3kaktmtorpathway

Ejemplares similares